| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
For analytical chemistry purposes, the "target" is the analyte of interest (2-Methylbutyryl-L-carnitine). The deuterated (d3) internal standard has nearly identical physicochemical properties (extraction efficiency, chromatography retention time, ionization efficiency) as the non-labeled analyte, but is distinguishable by mass spectrometry due to the mass shift, enabling precise quantification.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
The "activity" is not biological but analytical. It exhibits identical extraction recovery, chromatographic retention time, and ionization response as the natural compound (within batch-to-batch variability). It does not bind to or inhibit any biological enzyme. It is chemically stable and does not degrade during typical sample preparation protocols. |
| ln Vivo |
There are no in vivo pharmacological activities of interest as this compound is not a drug candidate; it is strictly an analytical reagent. If administered in vivo, it would be metabolized identically to endogenous 2-Methylbutyryl-L-carnitine, but it is not intended for dosing in living animals. Its use is confined to the bioanalysis of biological samples.
|
| Enzyme Assay |
A typical LC-MS/MS assay protocol involves adding a known amount of the deuterated internal standard (d3) to biological samples (e.g., plasma, urine, tissue homogenate). After protein precipitation with organic solvent (e.g., acetonitrile) and centrifugation, the supernatant is injected into an LC-MS/MS system equipped with a C18 column. The internal standard is monitored in MRM mode.
|
| Cell Assay |
Standard curves are prepared by spiking known concentrations of the non-labeled analyte into blank matrix, along with a fixed concentration of the internal standard. The internal standard is added to all samples, standards, and QCs at the beginning of the extraction process. The peak area ratio of analyte to internal standard is plotted versus nominal concentration. The linearity (R2 > 0.99), accuracy (85-115%), and precision (CV < 15%) must meet acceptance criteria.
|
| Animal Protocol |
As an analytical internal standard, (2S)-N3-IsoSer is not used in animal experiments as a therapeutic agent. It is used in "preclinical" settings as a tool for analyzing pharmacokinetic and pharmacodynamic data. Specifically, it is used to quantify levels of endogenous or exogenous 2-Methylbutyryl-L-carnitine in samples taken from animals treated with other compounds.
|
| ADME/Pharmacokinetics |
The key properties include high isotopic enrichment (typically >99 atom % D), chemical stability under recommended storage conditions (long-term stability at -20degC), and chromatographic co-elution with the non-labeled analyte. It is a stable isotope compound. It does not have classic PK parameters (AUC, Cmax, t1/2) as it is not dosed in vivo as a therapeutic.
|
| Toxicity/Toxicokinetics |
Toxicity data is not applicable as the compound is used in vitro for mass spectrometry analysis at nanomolar to micromolar concentrations and is not administered to living systems for therapeutic effect. The compound is considered non-toxic for its intended analytical use. Standard laboratory safety precautions for handling fine chemicals apply.
|
| References | |
| Additional Infomation |
(+/-)-2-Methylbutyryl-L-carnitine-d3 chloride is a specialized stable isotope-labeled biochemical. It is not a drug, has no FDA approval for therapy, and is not in clinical trials. It is manufactured for research use only (RUO). It is used as an internal standard for the quantification of 2-Methylbutyryl-L-carnitine (a metabolite involved in fatty acid oxidation disorders) by GC-MS or LC-MS in clinical metabolomics and newborn screening research.
|
| Molecular Formula |
C12H21D3CLNO4
|
|---|---|
| Molecular Weight |
284.79
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5114 mL | 17.5568 mL | 35.1136 mL | |
| 5 mM | 0.7023 mL | 3.5114 mL | 7.0227 mL | |
| 10 mM | 0.3511 mL | 1.7557 mL | 3.5114 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
